- Home
- Urologic Oncology
- Immunotherapy
The Latest Immunotherapy Research
Recent Abstracts
-
[Immunotherapy in the treatment of genitourinary cancers].ImmunotherapyMarch 10, 2016
-
Immunotherapy in prostate cancer: challenges and opportunities.ImmunotherapyDecember 9, 2015
-
Prospects for the Future of Prostate Cancer Vaccines.ImmunotherapyNovember 15, 2015
-
Vaccines, Adjuvants, and Dendritic Cell Activators-Current Status and Future Challenges.ImmunotherapyNovember 5, 2015
-
Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.ImmunotherapyOctober 27, 2015
-
What risk of prostate cancer led urologist to recommend prostate biopsies?ImmunotherapyOctober 6, 2015
-
Quality of preventive care before and after prostate cancer diagnosis.ImmunotherapyOctober 6, 2015
-
The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future.ImmunotherapyOctober 6, 2015
-
PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.ImmunotherapyOctober 6, 2015
-
Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy.ImmunotherapyOctober 6, 2015
Beyond the Abstracts
-
Exploiting synergy: the promise of immunogenic intensification in the treatment of prostate cancer - Beyond the AbstractImmunotherapyAugust 20, 2015
-
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy "Beyond the Abstract," by Stefanie Mandl, PhDImmunotherapyMarch 4, 2015
-
A therapeutic vaccine for prostate cancer: Immune impact induced by PROSTVAC (PSA-TRICOM), "Beyond the Abstract," by James L. Gulley, MD, PhDImmunotherapyAugust 21, 2014
-
The Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial: Lower baseline prostate-specific antigen Is associated with a greater overall survival benefit from sipuleucel-T, "Beyond the Abstract," by Philip W. Kantoff, MDImmunotherapyOctober 28, 2013
-
Analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer indicates sipuleucel-T immune parameters correlate with survival, "Beyond the Abstract," by Mayer N. Fishman, MD, PhD, et al.ImmunotherapyApril 10, 2013
-
Beyond the Abstract - Development of novel immune interventions for prostate cancer, by Neeraj Agarwal and Nicholas J. VogelzangImmunotherapyAugust 15, 2012